Braidwell LP Terns Pharmaceuticals, Inc. Transaction History

Braidwell LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$3.37 - $6.86 $1.76 Million - $3.58 Million	-522,002 Reduced 18.38%	2,318,050 $15 Billion
Q3 2023 Nov 14, 2023	BUY	$4.7 - $8.55 $4.69 Million - $8.53 Million	997,700 Added 54.15%	2,840,052 $14.3 Billion
Q2 2023 Aug 14, 2023	SELL	$7.35 - $13.29 $1.14 Million - $2.06 Million	-154,703 Reduced 7.75%	1,842,352 $16.1 Billion
Q1 2023 May 15, 2023	BUY	$7.91 - $12.0 $15.8 Million - $24 Million	1,997,055 New	1,997,055 $23.6 Billion

167

78.3M

580K

454K

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $216M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

Get notified when there are updates to the investment portfolio of Braidwell LP, based on Form 13F filings with the SEC.

Stay updated on Braidwell LP with notifications on news.